Likewise, treatment with recombinant Wnt3a stimulates bone formation and attenuates multiple myeloma cell growth in myelomatous severe combined immunodeficiency (SCID)-hu mice [72]. This evidence concerns the gene WNT3A and plasma cell myeloma.